The diagnosis was based on clinical presentation, such as attention deficit hyperactivity disorder, cognitive delay, and characteristic craniofacial features, and confirmed by the presence of a de novo mutation in the SMARCA2 gene through whole-exome sequencing. The gene discussed is SMARCA2; the disease is attention deficit-hyperactivity disorder.